Speransa Therapeutics

Speransa Therapeutics is a private, commercial-stage biotech company founded in 2018 and headquartered in Cambridge, Massachusetts. The company has developed and is commercializing the S.T. Genesis, an FDA-cleared, wearable neurostimulation device applied to the outer ear to alleviate symptoms of opioid withdrawal over a five-day period. Its business model centers on the distribution and support of this medical device, targeting the substantial market need for non-pharmacological opioid use disorder (OUD) treatment aids. The company appears to be in an early revenue-generating phase, focusing on provider adoption, reimbursement support, and patient access.

Percutaneous Nerve Field Stimulator (PNFS): A non-invasive, wearable neuromodulation device applied to the outer ear to deliver electrical stimulation, targeting cranial nerves to modulate brain activity associated with pain and anxiety during opioid withdrawal.

Speransa competes in the opioid withdrawal management space against established pharmacological therapies (e.g., buprenorphine, methadone, alpha-2 agonists like clonidine) and other neuromodulation devices (e.g., NSS-2 Bridge, which also targets ear nerves). Its key differentiator is the 5-day continuous wear time. Success requires convincing providers to adopt a device-based adjunct in a field dominated by drug protocols.